接受新型靶向治疗的成人急性髓系白血病患者的抗真菌预防:欧洲血液学协会的系统评价与专家共识推荐
欧洲血液学协会委托感染、血液、肿瘤、临床药理与方法学专家,按Cochrane方法系统检索MEDLINE、Embase和Cochrane图书馆(建库至2020年3月10日)随机对照试验和系统评价,采用GRADE Evidence to Decision框架制定推荐。针对去甲基化药物、米哚妥林和维奈克拉-去甲基化药物联合方案形成循证推荐,其他药物按复发/难治、单药、联合化疗等特定场景形成共识声明。多数场景中等强度推荐抗真菌预防,新型抗白血病药联合强化诱导化疗时强烈推荐;对艾伏尼布、来他替尼、奎扎替尼和维奈克拉,中等推荐在使用三唑类期间调整抗白血病药剂量。
要点
- 多数场景中等强度推荐抗真菌预防;新型急性髓系白血病药物联合强化诱导化疗时强烈推荐抗真菌预防。
- 对艾伏尼布、来他替尼、奎扎替尼和维奈克拉,中等推荐在使用三唑类抗真菌药期间调整抗白血病药物剂量。
- 循证推荐针对去甲基化药物、米哚妥林及维奈克拉-去甲基化药物联合方案;其他药物按复发/难治、单药或联合化疗场景给出共识声明。
- 许多新型靶向药物经细胞色素P450代谢,与三唑类的潜在药物相互作用及风险获益比尚未在临床试验中评估。
- 未来需纳入治疗药物监测的研究,以确定联用CYP3A4抑制性抗真菌药时调整新型抗白血病药物剂量对不良反应和缓解状态的作用。
适用人群与场景
- 接受新型靶向药物治疗的成人急性髓系白血病患者。
- 证据审查覆盖对急性髓系白血病有活性的新型药物,按以下结局评估:侵袭性真菌病发生率、住院延长、重症监护室住院天数、侵袭性真菌病所致死亡、生活质量及潜在药物相互作用。
- 系统检索排除非英文发表的研究。
处置流程与药物剂量
- 抗真菌预防在多数场景中等强度推荐。
- 若新型急性髓系白血病药物与强化诱导化疗联合使用,强烈推荐抗真菌预防。
- 对艾伏尼布、来他替尼、奎扎替尼和维奈克拉,中等推荐在使用三唑类期间调整抗白血病药物剂量。
- 针对去甲基化药物、米哚妥林及维奈克拉-去甲基化药物联合方案制定循证推荐;其他药物按复发/难治急性髓系白血病、单药治疗及联合化疗等特定治疗场景给出共识声明。
研究设计与关键结果
- 欧洲血液学协会委托感染性疾病、血液学、肿瘤学、临床药理学和方法学专家制定推荐。
- 按Cochrane方法进行系统文献综述,检索MEDLINE、Embase和Cochrane图书馆(含CENTRAL),纳入建库至2020年3月10日发表的随机对照试验和系统评价,排除非英文发表的研究。
- 采用GRADE Evidence to Decision框架制定推荐和共识声明,针对每种靶向药物及每个特定场景分别编写。
- 为去甲基化药物、米哚妥林和维奈克拉-去甲基化药物联合方案制定循证推荐;其他药物按复发/难治、单药、联合化疗等特定治疗场景给出共识声明。
- 抗真菌预防在多数场景中等强度推荐,新型药物联合强化诱导化疗时强烈推荐。
- 对艾伏尼布、来他替尼、奎扎替尼和维奈克拉,中等推荐在使用三唑类期间调整抗白血病药物剂量。
证据类型、等级与局限
- 证据类型:系统评价与专家共识推荐(指南)。
- 方法:按Cochrane方法系统检索,采用GRADE Evidence to Decision框架制定推荐。
- 局限:许多新型靶向药物经细胞色素P450代谢,潜在药物相互作用及风险获益比尚未在临床试验中评估;未来需纳入治疗药物监测的研究,以确定联用CYP3A4抑制性抗真菌药时调整新型抗白血病药物剂量对不良反应和缓解状态的作用。
对床旁实践的改变
- 对接受新型靶向药物治疗的成人急性髓系白血病患者,作者推荐在多数场景进行抗真菌预防(中等强度推荐);当新型药物与强化诱导化疗联合使用时,强烈推荐抗真菌预防。
- 对使用艾伏尼布、来他替尼、奎扎替尼或维奈克拉的患者,作者中等推荐在使用三唑类抗真菌药期间调整抗白血病药物剂量。
- 对去甲基化药物、米哚妥林及维奈克拉-去甲基化药物联合方案,按循证推荐执行;其他药物按复发/难治、单药或联合化疗等特定场景的共识声明处理。
指南或共识出处
- 指南名称:接受新型靶向治疗的成人急性髓系白血病患者的抗真菌预防:欧洲血液学协会的系统评价与专家共识推荐(Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association)。
- 发布机构:欧洲血液学协会(European Hematology Association)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
On the basis of improved overall survival, treatment guidelines strongly recommend antifungal prophylaxis during remission induction chemotherapy for patients with acute myeloid leukaemia. Many novel targeted agents are metabolised by cytochrome P450, but potential drug-drug interactions (DDIs) and the resulting risk-benefit ratio have not been assessed in clinical trials, leading to uncertainty in clinical management. Consequently, the European Haematology Association commissioned experts in the field of infectious diseases, haematology, oncology, clinical pharmacology, and methodology to develop up-to-date recommendations on the role of antifungal prophylaxis and management of pharmacokinetic DDIs with triazole antifungals. A systematic literature review was performed according to Cochrane methods, and recommendations were developed by use of the Grading of Recommendations Assessment, Development and Evaluation Evidence to Decision framework. We searched MEDLINE, Embase, and Cochrane Library, including Central Register of Controlled Trials, for randomised controlled trials and systematic reviews published from inception to March 10, 2020. We excluded studies that were not published in English. Evidence for any identified novel agent that is active against acute myeloid leukaemia was reviewed for the following outcomes: incidence of invasive fungal disease, prolongation of hospitalisation, days spent in intensive-care unit, mortality due to invasive fungal disease, quality of life, and potential DDIs. Recommendations and consensus statements were compiled for each targeted drug for patients with acute myeloid leukaemia and each specific setting. Evidence-based recommendations were developed for hypomethylating agents, midostaurin, and the venetoclax-hypomethylating agent combination. For all other agents, consensus statements were given for specific therapeutic settings, specifically for the management of patients with relapsed or refractory acute myeloid leukaemia, monotherapy, and combination with chemotherapy. Antifungal prophylaxis is recommended with moderate strength in most settings, and strongly recommended if the novel acute myeloid leukaemia agent is administered in combination with intensive induction chemotherapy. For ivosidenib, lestaurtinib, quizartinib, and venetoclax, we moderately recommend adjusting the dose of the antileukaemic agent during administration of triazoles. This is the first guidance supporting clinical decision making on antifungal prophylaxis in recipients of novel targeted drugs for acute myeloid leukaemia. Future studies including therapeutic drug monitoring will need to determine the role of dosage adjustment of novel antileukaemic drugs during concomitant administration of CYP3A4-inhibiting antifungals with respect to adverse effects and remission status.
参考来源
- Stemler J, de Jonge N, Skoetz N, et al. Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. Lancet Haematol. 2022. PMID: 35483397. doi:10.1016/S2352-3026(22)00073-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。